

Antoni Bayés-Genís

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3853323/publications.pdf>

Version: 2024-02-01

725
papers

27,544
citations

10389
72
h-index

11308
136
g-index

783
all docs

783
docs citations

783
times ranked

22751
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2023, 76, 121-123.	0.6	0
2	Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. <i>European Journal of Internal Medicine</i> , 2022, 95, 67-73.	2.2	10
3	Transition to heart failure in hypertension: going to the heart of the matter. <i>European Heart Journal</i> , 2022, 43, 3332-3334.	2.2	6
4	Long COVID-19 and microvascular disease-related angina. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, 75, 444-446.	0.6	14
5	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 20.	1.6	2
6	Perfil lipoproteico por espectroscopia nuclear magnética en pacientes con insuficiencia cardiaca crónica comparado con controles apareados. <i>Revista Espanola De Cardiologia</i> , 2022, , .	1.2	0
7	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2022, 11, 784.	2.4	4
8	Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. <i>Medicina Clínica</i> , 2022, 159, 157-163.	0.6	1
9	Sex-Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum. <i>Journal of the American Heart Association</i> , 2022, 11, e022404.	3.7	7
10	Dysglycaemia and high natriuretic peptides: the prelude to heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 254-256.	7.1	4
11	Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction. <i>Scientific Reports</i> , 2022, 12, 1344.	3.3	7
12	Mechanisms governing the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles: A scoping review of preclinical evidence. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112683.	5.6	13
13	Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. , 2022, 1, 28-44.		32
14	Commentary: A Review of Prognosis Model Associated With Cardiogenic Shock After Acute Myocardial Infarction. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856592.	2.4	0
15	Cardiac remodelling—Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	7.1	29
16	Response by Vilalta et al to Letter Regarding Article, “Midterm Outcomes Following Sutureless and Transcatheter Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.” <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS122011850.	3.9	0
17	Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation. <i>Scientific Reports</i> , 2022, 12, 4377.	3.3	2
18	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. <i>Scientific Reports</i> , 2022, 12, 4691.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Finding a reliable assay for soluble neprilysin. Clinical Biochemistry, 2022, 104, 51-58.	1.9	1
20	Urinary NGAL in acute heart failure revisited: the game is not over yet. International Journal of Cardiology, 2022, 357, 113-114.	1.7	2
21	Cardiovascular Complications of Interatrial Conduction Block. Journal of the American College of Cardiology, 2022, 79, 1199-1211.	2.8	18
22	Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the MyocardialIRON Trial. Journal of the American Heart Association, 2022, 11, e022214.	3.7	5
23	Clinical translation of mesenchymal stromal cell extracellular vesicles: Considerations on scientific rationale and production requisites. Journal of Cellular and Molecular Medicine, 2022, 26, 937-939.	3.6	4
24	Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2063-2069.	3.1	22
25	Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators. Frontiers in Cardiovascular Medicine, 2022, 9, 836451.	2.4	3
26	Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761.	7.1	27
27	Fulminant myocarditis in adults: a narrative review.. Journal of Geriatric Cardiology, 2022, 19, 137-151.	0.2	4
28	Translational proteomics in cardiogenic shock: from benchmark to bedside.. Journal of Geriatric Cardiology, 2022, 19, 158-162.	0.2	0
29	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	7.1	22
30	Circulating levels and prognostic cut-offs of sST2, hsTnT, and NT-proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	3.1	15
31	Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis. Journal of Clinical Medicine, 2022, 11, 2559.	2.4	0
32	Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation. Scientific Reports, 2022, 12, 7910.	3.3	1
33	Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	7.1	18
34	Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Failure, 2022, 9, 2170-2180.	3.1	17
35	Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO ₂): a randomized clinical trial. European Journal of Heart Failure, 2022, 24, 1816-1826.	7.1	22
36	Incidence, predictors and prognostic value of permanent pacemaker implantation following sutureless valve implantation in low-risk aortic stenosis patients. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	2

#	ARTICLE	IF	CITATIONS
37	Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis. <i>Nutrients</i> , 2022, 14, 2244.	4.1	4
38	La ecografía pulmonar en el seguimiento de la congestión pulmonar subclínica de pacientes ambulatorios con insuficiencia cardiaca. <i>Revista Española De Cardiología (English Ed)</i> , 2022, , .	0.6	0
39	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. <i>Cancers</i> , 2022, 14, 2941.	3.7	4
40	Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 3558.	2.4	5
41	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1067-1076.	2.6	40
42	Prognostic value of lung ultrasound in chronic stable ambulatory heart failure patients. <i>Revista Española De Cardiología (English Ed)</i> , 2021, 74, 862-869.	0.6	4
43	Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies. <i>Clinical Research in Cardiology</i> , 2021, 110, 1181-1192.	3.3	26
44	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 497-504.	4.9	10
45	Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction. <i>Revista Española De Cardiología (English Ed)</i> , 2021, 74, 616-623.	0.6	4
46	The pre-HFpEF stage: a new entity that requires proper phenotyping for better management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 935-936.	1.8	6
47	Longitudinal strain in remote non-infarcted myocardium by tissue tracking CMR: characterization, dynamics, structural and prognostic implications. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 241-253.	1.5	4
48	Transitioning from a coronary to a critical cardiovascular care unit: trends over the past three decades. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 437-444.	1.0	5
49	Sex-Related Differences in the Mechanism of Functional Tricuspid Regurgitation. <i>Heart Lung and Circulation</i> , 2021, 30, e16-e22.	0.4	18
50	Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. <i>Journal of Cardiac Failure</i> , 2021, 27, 427-434.	1.7	9
51	Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13464.	3.4	24
52	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	1.7	19
53	Implicaciones clínicas del bloqueo interauricular avanzado: síndrome de Bayà@. <i>Medicina Clínica</i> , 2021, 156, 233-234.	0.6	0
54	Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives. <i>Thorax</i> , 2021, 76, 196-200.	5.6	19

#	ARTICLE	IF	CITATIONS
55	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT@CHF. European Journal of Heart Failure, 2021, 23, 43-57.	7.1	19
56	Previously Undetected Obstructive Sleep Apnea in Patients With New-Onset Atrial Fibrillation. American Journal of Cardiology, 2021, 138, 46-52.	1.6	1
57	Thirst and factors associated with frequent thirst in patients with heart failure in Spain. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 86-91.	1.6	9
58	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	7.1	181
59	Neprilysin Inhibitors. , 2021, , 1-8.		0
60	Effect of COMBInAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI). Basic Research in Cardiology, 2021, 116, 4.	5.9	25
61	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-term Survival. Journal of the American Heart Association, 2021, 10, e019949.	3.7	18
62	Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure. JACC: Heart Failure, 2021, 9, 85-95.	4.1	12
63	Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. Frontiers in Cardiovascular Medicine, 2021, 8, 604434.	2.4	7
64	Meteorin-like/Meteorin- β^2 protects heart against cardiac dysfunction. Journal of Experimental Medicine, 2021, 218, .	8.5	33
65	Persistent chest pain after recovery of COVID-19: microvascular disease-related angina?. European Heart Journal - Case Reports, 2021, 5, ytab105.	0.6	15
66	Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure. Scientific Reports, 2021, 11, 3141.	3.3	20
67	Reply. Journal of the American College of Cardiology, 2021, 77, 1026-1028.	2.8	0
68	Preload dependence of pulmonary haemodynamics and right ventricular performance. Clinical Research in Cardiology, 2021, 110, 591-600.	3.3	1
69	Implante percutáneo de válvula en válvula por fallo de bioprótesis aortica sin sutura: serie de casos. Revista Espanola De Cardiologia, 2021, 74, 269-272.	1.2	1
70	Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell, 2021, 184, 1348-1361.e22.	28.9	149
71	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	3
72	Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury. Journal of Cardiovascular Pharmacology, 2021, 77, 332-333.	1.9	2

#	ARTICLE	IF	CITATIONS
73	Iron deficiency and short-term adverse events in patients with decompensated heart failure. Clinical Research in Cardiology, 2021, 110, 1292-1298.	3.3	9
74	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology, 2021, 110, 1280-1291.	3.3	20
75	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. Scientific Reports, 2021, 11, 5940.	3.3	2
76	Atypical advanced interatrial block due to giant atrial lipoma. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 737-739.	1.2	10
77	Clinical implications of advanced interatrial block: Bayà@'s syndrome. Medicina Clànica (English) Tj ETQq1 1 0.784314 rgBT /Overlock 10		
78	Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 1747-1759.	2.8	111
79	CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 475-483.	1.0	18
80	The <scp>CONCERTâ€HF</scp> trial: a sweet and sour symphony. European Journal of Heart Failure, 2021, 23, 675-676.	7.1	1
81	Professor Bernard Lown. Journal of the American College of Cardiology, 2021, 77, 1689-1690.	2.8	0
82	Awake venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 585-594.	1.0	18
83	Heart failure is ejection fraction in motion. European Journal of Heart Failure, 2021, 23, 564-566.	7.1	4
84	EpCAM and microvascular obstruction in patients with STEMI: a cardiac magnetic resonance study. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.6	1
85	Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?. PLoS ONE, 2021, 16, e0249674.	2.5	1
86	Sex differences on new-onset heart failure in patients with known or suspected coronary artery disease. European Journal of Preventive Cardiology, 2021, 28, 1711-1719.	1.8	18
87	Prognostic value of reverse remodelling criteria in heart failure with reduced or midâ€range ejection fraction. ESC Heart Failure, 2021, 8, 3014-3025.	3.1	11
88	Editorial: The Role of Sex in Heart Failure and Transplantation. Frontiers in Cardiovascular Medicine, 2021, 8, 690438.	2.4	2
89	Our Journey Through Advanced Therapies to Reduce Post-Infarct Scarring. Stem Cell Reviews and Reports, 2021, 17, 1928-1930.	3.8	1
90	Reply. JACC: Heart Failure, 2021, 9, 407-408.	4.1	0

#	ARTICLE	IF	CITATIONS
91	Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain. <i>ESC Heart Failure</i> , 2021, 8, 2492-2501.	3.1	7
92	Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 589-594.	0.2	4
93	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
94	Decoding empagliflozinâ€™s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 12025.	3.3	23
95	ComparaciÃ³n entre CA125 y NT-proBNP para valorar la congestiÃ³n en insuficiencia cardÃ¡aca aguda. <i>Medicina Clínica</i> , 2021, 156, 589-594.	0.6	18
96	Trayectoria precoz del sodio urinario y riesgo de eventos adversos en insuficiencia cardiaca aguda y disfunciÃ³n renal. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 616-623.	1.2	2
97	Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis. <i>Cardiology Journal</i> , 2021, 28, 566-578.	1.2	7
98	Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1090-1098.	1.7	3
99	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1747-1760.	2.3	10
100	Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. <i>European Journal of Heart Failure</i> , 2021, 23, 1445-1457.	7.1	60
101	Endocarditis on a Perceval S sutureless prosthesis. A new valve with a new form of clinical presentation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 635-637.	0.6	1
102	The â€˜Peptide for Lifeâ€™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across <scp>Europe</scp>. <i>European Journal of Heart Failure</i> , 2021, 23, 1432-1436.	7.1	10
103	Endocarditis sobre prÃ³tesis sin sutura Perceval S. Una nueva vÃ¡lvula con una nueva forma de presentaciÃ³n clÃ¡nica. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 635-637.	1.2	0
104	Usefulness of cardiac screening in patients with systemic lupus erythematosus and anti-Ro/SSA antibodies. <i>Lupus</i> , 2021, 30, 1596-1602.	1.6	2
105	Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 643-662.	2.8	40
106	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	2.2	5,558
107	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2021, 23, 1610-1632.	7.1	69
108	Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. <i>International Journal of Cardiology</i> , 2021, 339, 102-105.	1.7	11

#	ARTICLE	IF	CITATIONS
109	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1577-1596.	7.1	23
110	Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction. <i>Cells</i> , 2021, 10, 2571.	4.1	8
111	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	4.1	20
112	Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1192-1202.	10.7	28
113	Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. <i>European Journal of Internal Medicine</i> , 2021, 92, 94-99.	2.2	4
114	Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction. <i>Bioactive Materials</i> , 2021, 6, 3314-3327.	15.6	40
115	Head-to-head comparison of contemporary heart failure risk scores. <i>European Journal of Heart Failure</i> , 2021, 23, 2035-2044.	7.1	26
116	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. <i>Scientific Reports</i> , 2021, 11, 732.	3.3	14
117	Atrioventricular Node Ablation to Enhance Resynchronization Therapy Response in a Patient With Complete Atrioventricular Block. <i>JACC: Case Reports</i> , 2021, 3, 150-155.	0.6	0
118	A new option for monitoring heart failure. First experience in Spain with CardioMEMS. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 26-28.	0.2	0
119	A new option for monitoring heart failure. First experience in Spain with CardioMEMS. <i>Medicina Clínica</i> , 2021, 156, 26-28.	0.6	1
120	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 23, 74-84.	1.2	17
121	¹ H-magnetic resonance spectroscopy lipoprotein profile in patients with chronic heart failure versus matched controls. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, ,.	0.6	1
122	<scop>COVID</scop> vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	7.1	32
123	Midterm Outcomes Following Sutureless and Transcatheter Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011120.	3.9	11
124	Marathon Running Increases Synthesis and Decreases Catabolism of Joint Cartilage Type II Collagen Accompanied by High-Energy Demands and an Inflammatory Reaction. <i>Frontiers in Physiology</i> , 2021, 12, 722718.	2.8	7
125	Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind. <i>European Journal of Heart Failure</i> , 2021, 23, 1855-1857.	7.1	1
126	Lung ultrasound in outpatients with heart failure: the wet-to-dry HF study. <i>ESC Heart Failure</i> , 2021, 8, 4506-4516.	3.1	7

#	ARTICLE	IF	CITATIONS
127	Right ventricular function and iron deficiency in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 406-414.	1.0	8
128	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Frontiers in Cardiovascular Medicine, 2021, 8, 754499.	2.4	30
129	Prevalence and factors associated with atrial mitral and tricuspid regurgitation in patients with atrial fibrillation. Echocardiography, 2021, 38, 2043-2051.	0.9	3
130	Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction. Cells, 2021, 10, 3268.	4.1	1
131	Effect of β_2 -Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 2042-2056.	2.8	97
132	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	1.5	1
133	The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction. Scientific Reports, 2021, 11, 22155.	3.3	1
134	Neprilysin Inhibitors., 2021, , 1075-1082.	0	
135	α -Peptide for Life™ in primary care: work in progress. European Heart Journal, 2021, , .	2.2	5
136	Spotlight on epigenetic reprogramming in cardiac regeneration. Seminars in Cell and Developmental Biology, 2020, 97, 26-37.	5.0	8
137	Differential prognostic impact of type 2 diabetes mellitus in women and men with heart failure with preserved ejection fraction. Revista Espanola De Cardiologia (English Ed), 2020, 73, 463-470.	0.6	12
138	Renal denervation for the treatment of resistant hypertension in Spain. The Flex-Spyral Registry. Revista Espanola De Cardiologia (English Ed), 2020, 73, 615-622.	0.6	2
139	Denervació renal para el tratamiento de la hipertensió arterial resistente en España. Registro Flex-Spyral. Revista Espanola De Cardiologia, 2020, 73, 615-622.	1.2	3
140	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. Revista Espanola De Cardiologia (English Ed), 2020, 73, 313-323.	0.6	10
141	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. American Journal of Medicine, 2020, 133, 370-380.e4.	1.5	58
142	Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind. International Journal of Cardiology, 2020, 300, 198-200.	1.7	0
143	Atrial Failure as a Clinical Entity. Journal of the American College of Cardiology, 2020, 75, 222-232.	2.8	174
144	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	7.1	26

#	ARTICLE	IF	CITATIONS
145	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	7.1	81
146	Molecular signature of cardiogenic shock. European Heart Journal, 2020, 41, 3839-3848.	2.2	20
147	Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study. ESC Heart Failure, 2020, 7, 118-123.	3.1	14
148	Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?. European Journal of Heart Failure, 2020, 22, 276-278.	7.1	2
149	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. Revista Espanola De Cardiologia (English Ed), 2020, 73, 248-254.	0.6	4
150	Short- and long-term mortality in patients with left-sided infective endocarditis not undergoing surgery despite indication. Revista Espanola De Cardiologia (English Ed), 2020, 73, 734-740.	0.6	6
151	Chronotropic Incompetence Predicts Distance Walked in Six-Minute Walk Test in Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2020, 26, 1024-1025.	1.7	4
152	Hiperpotasemia en pacientes con insuficiencia cardiaca en España y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term. Revista Espanola De Cardiologia, 2020, 73, 313-323.	1.2	16
153	Magnetic Resonance Imaging-Guided Fibrosis Ablation for the Treatment of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008707.	4.8	44
154	Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial. ESC Heart Failure, 2020, 7, 4222-4230.	3.1	21
155	Circulating Marine and Vegetable Omega-3 at the Time of ST-Segment Elevation Myocardial Infarction and Incident Hard Clinical Endpoints. Current Developments in Nutrition, 2020, 4, nzaa061_111.	0.3	0
156	Sacubitril/Valsartan as Antifibrotic Drug. Journal of the American College of Cardiology, 2020, 76, 515-517.	2.8	4
157	First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. EBioMedicine, 2020, 54, 102729.	6.1	27
158	Identifying very low-risk STEMI patients for early ICU discharge in the COVID-19 era. Clinical Research in Cardiology, 2020, 109, 1582-1584.	3.3	0
159	What every clinician should know about Bayà's syndrome. Revista Espanola De Cardiología (English Ed) Tj ETQq1 0.784314 rgBT / Ov	0.6	0
160	Altered GDF15 and FGF21 Levels in Response to Strenuous Exercise: A Study in Marathon Runners. Frontiers in Physiology, 2020, 11, 550102.	2.8	16
161	Trends in Short- and Long-Term ST-segment-Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population-Based ST-segment-Elevation Myocardial Infarction Registry. Journal of the American Heart Association, 2020, 9, e017159.	3.7	16
162	Short- and Long-Term Mortality Trends in STEMI-Cardiogenic Shock over Three Decades (1989-2018): The Ruti-STEMI-Shock Registry. Journal of Clinical Medicine, 2020, 9, 2398.	2.4	14

#	ARTICLE	IF	CITATIONS
163	Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction. Open Heart, 2020, 7, e001169.	2.3	3
164	Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure. ESC Heart Failure, 2020, 7, 3320-3328.	3.1	2
165	Circulating Omega-3 Fatty Acids and Incident Adverse Events in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2020, 76, 2089-2097.	2.8	19
166	The impact of frailty in aortic valve surgery. BMC Geriatrics, 2020, 20, 426.	2.7	5
167	Relation of Interatrial Block to Cognitive Impairment in Patients â‰¥70 Years of Age (From the CAMBIAD) Tj ETQg1 1 0.784314 rgET	1.6	7
168	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92
169	Interatrial block and cognitive impairment in the BAYES prospective registry. International Journal of Cardiology, 2020, 321, 95-98.	1.7	21
170	Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. CardioRenal Medicine, 2020, 10, 362-372.	1.9	5
171	Renal function dynamics following coâ€¢administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. ESC Heart Failure, 2020, 7, 3792-3800.	3.1	11
172	Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Scientific Reports, 2020, 10, 13553.	3.3	21
173	Relationship Between Bioimpedance Vector Displacement and Renal Function After a Marathon in Non-elite Runners. Frontiers in Physiology, 2020, 11, 352.	2.8	10
174	Cardiovascular disease and COVID-19: les liaisons dangereuses. European Journal of Preventive Cardiology, 2020, 27, 1017-1025.	1.8	27
175	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. European Journal of Preventive Cardiology, 2020, , 204748732092761.	1.8	21
176	Lung Ultrasound for Heart Failure Diagnosis in Primary Care. Journal of Cardiac Failure, 2020, 26, 824-831.	1.7	13
177	Consenso de expertos sobre la insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n reducida: mÃ¡s allÃ¡ de las guÃ±as. Revista Espanola De Cardiologia Suplementos, 2020, 20, 1-46.	0.2	2
178	Clinical profile and 1-year clinical outcomes of super elderly patients admitted with acute heart failure. European Journal of Internal Medicine, 2020, 81, 78-82.	2.2	5
179	Highly sensitive troponin T dynamics and prognosis in asymptomatic severe aortic stenosis. Revista Espanola De Cardiologia (English Ed), 2020, 73, 1065-1066.	0.6	0
180	Clinical Role of CA125 in WorseningâHeartâFailure. JACC: Heart Failure, 2020, 8, 386-397.	4.1	57

#	ARTICLE	IF	CITATIONS
181	Relation of Advanced Interatrial Block to Risk of Atrial Fibrillation and Stroke. American Journal of Cardiology, 2020, 125, 1745-1748.	1.6	22
182	Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 831.	2.4	15
183	CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. International Journal of Cardiology, 2020, 308, 54-59.	1.7	28
184	Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction. ESC Heart Failure, 2020, 7, 1007-1014.	3.1	14
185	Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 437-447.	1.0	32
186	An outlook on biomarkers in cardiogenic shock. Current Opinion in Critical Care, 2020, 26, 392-397.	3.2	14
187	New Electrocardiographic Algorithm for the Diagnosis of Acute Myocardial Infarction in Patients With Left Bundle Branch Block. Journal of the American Heart Association, 2020, 9, e015573.	3.7	29
188	Neprilisin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Failure, 2020, 7, 559-566.	3.1	15
189	Mini Nutritional Assessment Short Form is a morbi-mortality predictor in outpatients with heart failure and mid-range left ventricular ejection fraction. Clinical Nutrition, 2020, 39, 3395-3401.	5.0	21
190	Urine: an overlooked biomedium in heart failure?. Biomarkers in Medicine, 2020, 14, 165-168.	1.4	1
191	Silk-Reinforced Collagen Hydrogels with Raised Multiscale Stiffness for Mesenchymal Cells 3D Culture. Tissue Engineering - Part A, 2020, 26, 358-370.	3.1	33
192	Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity. Metabolism: Clinical and Experimental, 2020, 106, 154191.	3.4	7
193	Differences in the Interleukin-1 β /Soluble ST2 Interplay Between Acute and Chronic Heart Failure. Journal of Cardiovascular Translational Research, 2020, 13, 864-866.	2.4	1
194	Decellularized pericardial extracellular matrix: The preferred porous scaffold for regenerative medicine. Xenotransplantation, 2020, 27, e12580.	2.8	6
195	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 835-843.	0.6	5
196	Response. The ST2-SCD score in ambulatory heart failure patients. International Journal of Cardiology, 2020, 300, 207.	1.7	0
197	Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction. Revista Espanola De Cardiologia (English Ed), 2020, 73, 561-568.	0.6	6
198	Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model. Scientific Reports, 2020, 10, 7166.	3.3	18

#	ARTICLE	IF	CITATIONS
199	Omics phenotyping in heart failure: the next frontier. European Heart Journal, 2020, 41, 3477-3484.	2.2	48
200	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. European Journal of Heart Failure, 2020, 22, 906-910.	7.1	5
201	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-CHF-CEORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	7.1	83
202	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-CEORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	7.1	36
203	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. Journal of Clinical Medicine, 2020, 9, 1110.	2.4	19
204	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. Cardiovascular Diabetology, 2020, 19, 38.	6.8	9
205	Macronutrient and mineral intake effects on racing time and cardiovascular health in non-elite marathon runners. Nutrition, 2020, 78, 110806.	2.4	3
206	Gender-Related Differences in Heart Failure Biomarkers. Frontiers in Cardiovascular Medicine, 2020, 7, 617705.	2.4	31
207	Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors. European Journal of Heart Failure, 2020, 22, 1214-1225.	7.1	17
208	Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. European Journal of Internal Medicine, 2020, 80, 91-98.	2.2	10
209	Efecto pronóstico diferencial de la diabetes mellitus tipo II en mujeres y varones con insuficiencia cardíaca y fracción de eyecisión conservada. Revista Española De Cardiología, 2020, 73, 463-470.	1.2	5
210	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. Revista Española De Cardiología, 2020, 73, 248-254.	1.2	8
211	Cambio en la causa de muerte e influencia de la mejora terapéutica con el tiempo en pacientes con insuficiencia cardíaca y fracción de eyecisión reducida. Revista Española De Cardiología, 2020, 73, 561-568.	1.2	9
212	Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal. European Heart Journal Supplements, 2020, 22, P29-P32.	0.1	10
213	Advanced interatrial block and P-wave duration are associated with atrial fibrillation and stroke in older adults with heart disease: the BAYES registry. Europace, 2020, 22, 1001-1008.	1.7	48
214	Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The MyocardialIRON Trial. Journal of the American Heart Association, 2020, 9, e014254.	3.7	58
215	Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right. European Cardiology Review, 2020, 15, e19.	2.2	9
216	Repeat physical stress echocardiography in asymptomatic severe aortic stenosis. Cardiology Journal, 2020, 27, 307-308.	1.2	0

#	ARTICLE	IF	CITATIONS
217	Dinàmica de troponina T de alta sensibilidad y pronòstico en pacientes con estenosis aòrtica grave asintomàtica. Revista Espanola De Cardiologia, 2020, 73, 1065-1066.	1.2	0
218	Heart Failure Treatment by Device. European Cardiology Review, 2020, 15, e17.	2.2	1
219	Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?. Journal of Circulating Biomarkers, 2020, 9, 8-12.	1.3	3
220	The overlooked tsunami of systemic inflammation in post-myocardial infarction cardiogenic shock. European Journal of Preventive Cardiology, 2020, , , .	1.8	1
221	Entrenamiento de la musculatura inspiratoria y la electroestimulaciòn muscular funcional en el tratamiento de la insuficiencia cardiaca con funciòn sistòlica conservada: estudio TRAINING-HF. Revista Espanola De Cardiologia, 2019, 72, 288-297.	1.2	23
222	Una intervenciòn precoz para reducir reingresos a los 30 dàas en pacientes ancianos frágiles con insuficiencia cardiaca mantiene su beneficio al aò±o. Revista Espanola De Cardiologia, 2019, 72, 261-263.	1.2	2
223	Razòn internacional normalizada y mortalidad de los pacientes con insuficiencia cardiaca y fibrilaciòn auricular tratados con antagonistas de la vitamina K. Revista Espanola De Cardiologia, 2019, 72, 616-624.	1.2	4
224	Left Atrial Dimension, Primary Mitral Regurgitation, and the Need of Early Surgery. Cardiology, 2019, 142, 239-241.	1.4	1
225	Mortality and Heart Failure Hospitalizations. The Need for an Exhaustive, Official, and Standardized Registry. Revista Espanola De Cardiologia (English Ed), 2019, 72, 988-990.	0.6	2
226	Reply. Journal of the American College of Cardiology, 2019, 74, 479-480.	2.8	0
227	External Validation of the ELANâ€HF Score, Predicting 6â€Month Allâ€Cause Mortality in Patients Hospitalized for Acute Decompensated Heart Failure. Journal of the American Heart Association, 2019, 8, e010309.	3.7	5
228	Airflow limitation in patients with heart failure: Prevalence and associated factors. Medicina Clànica (English Edition), 2019, 153, 191-195.	0.2	0
229	Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: an <i>in vitro</i> and <i>in vivo</i> study in aortic stenosis. Clinical Science, 2019, 133, 1537-1548.	4.3	25
230	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. European Journal of Heart Failure, 2019, 21, 1259-1266.	7.1	46
231	Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure. Clinical Chemistry, 2019, 65, 1187-1189.	3.2	2
232	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65
233	Microvascular Obstruction in ST-Segment Elevation Myocardial Infarction: Looking Back to Move Forward. Focus on CMR. Journal of Clinical Medicine, 2019, 8, 1805.	2.4	20
234	Resonance-Based Microwave Technique for Body Implant Sensing. Sensors, 2019, 19, 4828.	3.8	4

#	ARTICLE	IF	CITATIONS
235	Clinical and Prognostic Significance of sST2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2193-2203.	2.8	110
236	Epigenetic Biomarkers in Cardiovascular Diseases. <i>Frontiers in Genetics</i> , 2019, 10, 950.	2.3	79
237	Old teaching tools should not be forgotten: The value of the Lewis ladder diagram in understanding bigeminal rhythms. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12685.	1.1	4
238	Targeting social disadvantage to prevent early development of heart failure. <i>International Journal of Cardiology</i> , 2019, 293, 181-182.	1.7	1
239	Elastomeric cardiopatch scaffold for myocardial repair and ventricular support. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 57, 545-555.	1.4	13
240	Woven Coronary Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008087.	3.9	4
241	Circulating Galectin-3 Following Heart Transplant: Long-term Dynamics and Prognostic Value. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 899-906.	0.6	2
242	Determination of HLAâ€A, â€B, â€C, â€DRB1 and â€DQB1 allele and haplotype frequencies in heart failure patients. <i>ESC Heart Failure</i> , 2019, 6, 388-395.	3.1	9
243	Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1093-1101.	2.3	11
244	Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2019, 124, 567-572.	1.6	38
245	Protein-based cardiogenic shock patient classifier. <i>European Heart Journal</i> , 2019, 40, 2684-2694.	2.2	30
246	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	7.1	446
247	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
248	Acute heart failure congestion and perfusion statusâ€“Impact of the clinical classification on in-hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	7.1	170
249	A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. <i>International Journal of Cardiology</i> , 2019, 293, 148-152.	1.7	16
250	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	1.8	28
251	New electrocardiographic score for the prediction of atrial fibrillation: The MVP ECG risk score (morphologyâ€voltageâ€Pâ€wave duration). <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12669.	1.1	48
252	Prognostic of Interatrial Block after an Acute ST-Segment Elevation Myocardial Infarction. <i>Cardiology</i> , 2019, 142, 109-115.	1.4	17

#	ARTICLE	IF	CITATIONS
253	Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 130, 216-233.	1.9	14
254	Liquid Biopsy and eHealth in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2206-2208.	2.8	5
255	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
256	Distal Bioresorbable Vascular Scaffold Strut Embolization Detected at Late Follow-Up. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, e63-e65.	2.9	0
257	Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors. <i>Circulation: Heart Failure</i> , 2019, 12, e005652.	3.9	53
258	Carbohydrate antigen 125 in heart failure. A New era in the monitoring and control of treatment. <i>Medicina Clànica (English Edition)</i> , 2019, 152, 266-273.	0.2	2
259	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1016-1025.	2.8	52
260	Effects of a polysaccharide-based multi-ingredient supplement on salivary immunity in non-elite marathon runners. <i>Journal of the International Society of Sports Nutrition</i> , 2019, 16, 14.	3.9	5
261	Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2369-2382.	5.4	224
262	Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine. <i>Circulation Research</i> , 2019, 124, 938-951.	4.5	28
263	The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 202-207.	4.0	53
264	Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. <i>Heart</i> , 2019, 105, heartjnl-2018-314173.	2.9	81
265	Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2019, 291, 83-88.	1.7	16
266	Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	6
267	Magnetic resonance microscopy and correlative histopathology of the infarcted heart. <i>Scientific Reports</i> , 2019, 9, 20017.	3.3	4
268	Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2292.	7.4	85
269	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 447-451.	1.4	9
270	Mini nutritional assessment is a better predictor of mortality than subjective global assessment in heart failure out-patients. <i>Clinical Nutrition</i> , 2019, 38, 2740-2746.	5.0	30

#	ARTICLE	IF	CITATIONS
271	Toward Standardization of Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Therapeutic Use: A Call for Action. <i>Proteomics</i> , 2019, 19, e1800397.	2.2	16
272	Antígeno carbohidrato 125 en insuficiencia cardiaca. Nueva era en la monitorización y control del tratamiento. <i>Medicina Clínica</i> , 2019, 152, 266-273.	0.6	34
273	Trends in prevalence and outcomes of acute coronary syndrome associated with cocaine consumption: The RUTI-cocaine study. <i>International Journal of Cardiology</i> , 2019, 283, 23-27.	1.7	3
274	Circulating MiRNA Dynamics in ST-Segment Elevation Myocardial Infarction-driven Cardiogenic Shock. <i>Revista Española De Cardiología (English Ed)</i> , 2019, 72, 783-786.	0.6	3
275	Risk Estimation in Type 2 Myocardial Infarction and Myocardial Injury: The TARRACO Risk Score. <i>American Journal of Medicine</i> , 2019, 132, 217-226.	1.5	15
276	Circulating levels of <scp>microRNA</scp> 423â€‰p are associated with 90â€‰day mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2019, 6, 98-102.	3.1	15
277	Dinámica de microARN circulantes en pacientes con infarto agudo de miocardio con elevación del segmento ST con shock cardiológico. <i>Revista Española De Cardiología</i> , 2019, 72, 783-785.	1.2	5
278	Limitación al flujo aóreo en pacientes con insuficiencia cardíaca: prevalencia y factores asociados. <i>Medicina Clínica</i> , 2019, 153, 191-195.	0.6	1
279	High-sensitivity troponin T in asymptomatic severe aortic stenosis. <i>Biomarkers</i> , 2019, 24, 334-340.	1.9	10
280	Heartâ€“Lungâ€“Muscle Anti-SAE Syndrome: An Atypical Severe Combination. <i>Journal of Clinical Medicine</i> , 2019, 8, 20.	2.4	2
281	Hydrogen- and Methane-Based Breath Testing and Outcomes in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 319-327.	1.7	14
282	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	1.7	32
283	Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. <i>European Journal of Internal Medicine</i> , 2019, 60, 18-23.	2.2	11
284	Efecto inicial del sacubitrilo-valsartán sobre la capacidad funcional en pacientes con insuficiencia cardíaca con fracción de eyeción reducida: estudio piloto. <i>Revista Española De Cardiología</i> , 2019, 72, 167-169.	1.2	4
285	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. <i>Revista Española De Cardiología (English Ed)</i> , 2019, 72, 288-297.	0.6	12
286	Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study. <i>Revista Española De Cardiología (English Ed)</i> , 2019, 72, 167-169.	0.6	6
287	An Early Post-discharge Intervention Planned to Reduce 30-day Readmissions in old and Frail Heart Failure Patients Remains Beneficial at 1 Year. <i>Revista Española De Cardiología (English Ed)</i> , 2019, 72, 261-263.	0.6	1
288	Galectina-3 circulante tras el trasplante cardíaco: dinámica a largo plazo y valor pronóstico. <i>Revista Española De Cardiología</i> , 2019, 72, 899-906.	1.2	3

#	ARTICLE	IF	CITATIONS
289	Mortalidad y reingresos por insuficiencia cardiaca: la necesidad de un registro oficial completo, abierto y homologable. Revista Espanola De Cardiologia, 2019, 72, 988-990.	1.2	2
290	Growth differentiation factor 15 and early prognosis after out-of-hospital cardiac arrest. Annals of Intensive Care, 2019, 9, 119.	4.6	8
291	Contemporary Yield of 24-hour Holter Monitoring: Role of Inter-Atrial Block Recognition. Journal of Atrial Fibrillation, 2019, 12, 2225.	0.5	2
292	Interatrial shunting for heart failure: current evidence and future perspectives. EuroIntervention, 2019, 15, 164-171.	3.2	15
293	Myocardial healing using cardiac fat. Expert Review of Cardiovascular Therapy, 2018, 16, 305-311.	1.5	3
294	When the VEST Does Not Fit. Circulation: Heart Failure, 2018, 11, e005116.	3.9	2
295	Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. Clinical Cardiology, 2018, 41, 476-480.	1.8	27
296	Changes in myocardial iron content following administration of intravenous iron (MyocardialIRON): Study design. Clinical Cardiology, 2018, 41, 729-735.	1.8	15
297	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. European Heart Journal, 2018, 39, 1255-1264.	2.2	166
298	Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints. Clinical Research in Cardiology, 2018, 107, 437-443.	3.3	17
299	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. International Journal of Cardiology, 2018, 257, 188-192.	1.7	32
300	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
301	Impact of a life™ initiative on post-ST elevation myocardial infarction heart failure: a 15Âyear heart failure clinic experience. ESC Heart Failure, 2018, 5, 101-105.	3.1	2
302	Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management. European Journal of Heart Failure, 2018, 20, 433-435.	7.1	16
303	Unravelling the effects of mechanical physiological conditioning on cardiac adipose tissue-derived progenitor cells in vitro and in silico. Scientific Reports, 2018, 8, 499.	3.3	10
304	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace, 2018, 20, 1577-1583.	1.7	93
305	Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction. Cardiovascular Diabetology, 2018, 17, 63.	6.8	17
306	Carbohydrate Antigen-125 in Heart Failure. JACC: Heart Failure, 2018, 6, 441-442.	4.1	5

#	ARTICLE	IF	CITATIONS
307	Head-to-head comparison of two engineered cardiac grafts for myocardial repair: From scaffold characterization to pre-clinical testing. <i>Scientific Reports</i> , 2018, 8, 6708.	3.3	45
308	Heart Rate in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 350-351.	4.1	2
309	β_2 -Blocker treatment and prognosis in acute coronary syndrome associated with cocaine consumption: The RUTI-Cocaine Study. <i>International Journal of Cardiology</i> , 2018, 260, 7-10.	1.7	8
310	Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy. <i>Laboratory Investigation</i> , 2018, 98, 1291-1299.	3.7	26
311	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018, 39, 2793-2799.	2.2	26
312	Management of Nonagenarian Patients With Severe Aortic Stenosis: The Role of Comorbidity. <i>Heart Lung and Circulation</i> , 2018, 27, 219-226.	0.4	17
313	Peak Exercise Oxygen Uptake Predicts Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. <i>Revista Española De Cardiología (English Ed)</i> , 2018, 71, 250-256.	0.6	11
314	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. <i>Circulation</i> , 2018, 137, 1320-1330.	1.6	121
315	Iron status measurement in routine heart failure assessment: a call for action. <i>European Journal of Heart Failure</i> , 2018, 20, 123-124.	7.1	3
316	Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	7.1	20
317	Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. <i>European Journal of Heart Failure</i> , 2018, 20, 67-75.	7.1	63
318	Interatrial block, frailty and prognosis in elderly patients with myocardial infarction. <i>Journal of Electrocardiology</i> , 2018, 51, 1-7.	0.9	28
319	El consumo máximo de oxígeno predice los ingresos recurrentes por insuficiencia cardíaca con fractiòn de eyecciòn conservada. <i>Revista Española De Cardiología</i> , 2018, 71, 250-256.	1.2	13
320	NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure. <i>Circulation</i> , 2018, 137, 1671-1683.	1.6	122
321	Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study. <i>International Journal of Cardiology</i> , 2018, 252, 136-139.	1.7	44
322	Intermediate Care Unit After Cardiac Surgery: Impact on Length of Stay and Outcomes. <i>Revista Española De Cardiología (English Ed)</i> , 2018, 71, 638-642.	0.6	3
323	Arrhythmogenic right ventricular dysplasia/cardiomyopathy: an electrocardiogram-based review. <i>Europace</i> , 2018, 20, f3-f12.	1.7	22
324	Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 549-551.	1.7	0

#	ARTICLE	IF	CITATIONS
325	ST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	2.8	126
326	Letter by Fung et al Regarding Article, "Frailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysis". Journal of the American Medical Directors Association, 2018, 19, 1143-1146.	2.5	0
327	Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-analysis. Journal of the American Heart Association, 2018, 7, e008251.	3.7	140
328	Risk Stratification According to Midlife Physical Fitness in an Asymptomatic Population. Journal of the American College of Cardiology, 2018, 72, 3230-3231.	2.8	1
329	ST2 in Heart Failure. Circulation: Heart Failure, 2018, 11, e005582.	3.9	30
330	Asymptomatic severe aortic stenosis: biomarkers are welcome. Heart, 2018, 105, heartjnl-2018-314122.	2.9	4
331	Response by Náez et al to Letter Regarding Article, "Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality". Circulation, 2018, 138, 1613-1614.	1.6	1
332	Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness. ESC Heart Failure, 2018, 5, 1173-1175.	3.1	22
333	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
334	Circulating monocyte subsets and heart failure prognosis. PLoS ONE, 2018, 13, e0204074.	2.5	8
335	Ex vivo assessment and in vivo validation of non-invasive stent monitoring techniques based on microwave spectrometry. Scientific Reports, 2018, 8, 14808.	3.3	1
336	Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure Outpatients: A Cohort Analysis. Psychotherapy and Psychosomatics, 2018, 87, 372-374.	8.8	7
337	Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia, 2018, 10, e011044.	1.1	26
338	Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion. PLoS ONE, 2018, 13, e0206344.	2.5	25
339	Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. BMC Cardiovascular Disorders, 2018, 18, 206.	1.7	18
340	Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study. Scientific Reports, 2018, 8, 15115.	3.3	21
341	Myocardial Remodeling in Hypertension. Hypertension, 2018, 72, 549-558.	2.7	123
342	No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence. European Journal of Heart Failure, 2018, 20, 1252-1254.	7.1	5

#	ARTICLE	IF	CITATIONS
343	No urgent need for revisiting kalaemia guidelines: rebuttal. European Journal of Heart Failure, 2018, 20, 1256-1256.	7.1	1
344	Atypical advanced interatrial blocks: Definition and electrocardiographic recognition. Journal of Electrocardiology, 2018, 51, 1091-1093.	0.9	44
345	Use of acetazolamide in the treatment of patients with refractory congestive heart failure. Cardiovascular Therapeutics, 2018, 36, e12465.	2.5	13
346	Second-degree interatrial block: Brief review and concept. Annals of Noninvasive Electrocardiology, 2018, 23, e12583.	1.1	12
347	The Barcelona Bio-HF Calculator. JACC: Heart Failure, 2018, 6, 808-810.	4.1	4
348	Advanced interatrial block predicts new-onset atrial fibrillation and ischemic stroke in patients with heart failure: The â€œBayes' Syndrome-HFâ€•study. International Journal of Cardiology, 2018, 271, 174-180.	1.7	71
349	Evolutive echocardiographic changes in cardiac amyloidosis: Look at the whole picture. Echocardiography, 2018, 35, 1042-1044.	0.9	0
350	Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 176-185.	2.4	18
351	Primary Ventricular Fibrillation in the Primary Percutaneous Coronary Intervention ST-Segment Elevation Myocardial Infarction Era (from the â€œCodi IAMâ€•Multicenter Registry). American Journal of Cardiology, 2018, 122, 529-536.	1.6	13
352	The misperception of â€˜stableâ€™ heart failure. European Journal of Heart Failure, 2018, 20, 1375-1378.	7.1	9
353	ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. International Journal of Cardiology, 2018, 270, 336-342.	1.7	21
354	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 543-550.	2.0	16
355	Biomarkers and heartâ€“kidney interaction. European Heart Journal Supplements, 2018, 20, G28-G36.	0.1	1
356	Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. Journal of the American College of Cardiology, 2018, 72, 591-601.	2.8	132
357	A panel of multibiomarkers of inflammation, fibrosis, and catabolism is normal in healthy centenarians but has high values in young patients with myocardial infarction. Maturitas, 2018, 116, 54-58.	2.4	1
358	Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatrics, 2018, 18, 109.	2.7	33
359	Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes. Journal of Translational Medicine, 2018, 16, 35.	4.4	6
360	Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography, 2018, 35, 1736-1745.	0.9	6

#	ARTICLE	IF	CITATIONS
361	Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?. <i>Circulation</i> , 2018, 138, 551-553.	1.6	39
362	Left Ventricular Ejection Fraction in Heart Failure. <i>European Cardiology Review</i> , 2018, 13, 91.	2.2	0
363	Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw543.	2.2	148
364	Early serum creatinine changes and outcomes in patients admitted for acute heart failure: the cardio-renal syndrome revisited. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 430-440.	1.0	21
365	Assessment of respiratory flow cycle morphology in patients with chronic heart failure. <i>Medical and Biological Engineering and Computing</i> , 2017, 55, 245-255.	2.8	6
366	Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 685-696.	1.0	49
367	Fibrin, the preferred scaffold for cell transplantation after myocardial infarction? An old molecule with a new life. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 2304-2313.	2.7	36
368	Practical data handling pipeline improves performance of qPCR-based circulating miRNA measurements. <i>Rna</i> , 2017, 23, 811-821.	3.5	58
369	Early Postdischarge STOP-HF-Clinic Reduces 30-day Readmissions in Old and Frail Patients With Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 631-638.	0.6	21
370	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	4.1	104
371	The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 206-208.	2.4	47
372	Relationship among LRP1 expression, Pyk2 phosphorylation and MMP9 activation in left ventricular remodelling after myocardial infarction. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1915-1928.	3.6	12
373	Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	43
374	Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. <i>ESC Heart Failure</i> , 2017, 4, 66-70.	3.1	2
375	RAS Fingerprint. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3010-3011.	2.8	0
376	Minimally Invasive Adipose Graft Transposition Procedure. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 66-68.	2.4	2
377	Austrian Syndrome Complicated With a Periannular Mitral Abscess. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1136.	0.6	1
378	Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3000-3009.	3.6	9

#	ARTICLE	IF	CITATIONS
379	Iatrogenic pleuropericardial communication: A rare complication of percutaneous epicardial mapping. HeartRhythm Case Reports, 2017, 3, 196-198.	0.4	1
380	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 924-932.	0.6	12
381	EvaluaciÃ³n de los algoritmos de Smith para elÃ¡diagnÃ³stico deÂinfarto agudo deÂmiocardio enÂpresencia deÂbloqueo deÂrama izquierda delÂhaz deÂHis. Revista Espanola De Cardiologia, 2017, 70, 559-566.	1.2	7
382	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. European Journal of Heart Failure, 2017, 19, 1615-1623.	7.1	149
383	Assessment of Smith Algorithms for the Diagnosis of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block. Revista Espanola De Cardiologia (English Ed), 2017, 70, 559-566.	0.6	5
384	Characterization and classification of patients with different levels of cardiac death risk by using PoincarÃ© plot analysis. , 2017, 2017, 1332-1335.		4
385	Soluble ST2 for Prognosis and MonitoringÂin Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2389-2392.	2.8	43
386	Heart failure with midâ€¢range ejection fraction: a transition phenotype?. European Journal of Heart Failure, 2017, 19, 1635-1637.	7.1	16
387	The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	2.8	43
388	Reply. European Journal of Heart Failure, 2017, 19, 1736-1736.	7.1	0
389	Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	20
390	Functional Mitral Regurgitation Predicts Short-Term Adverse Events in Patients With Acute Heart Failure and Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2017, 120, 1344-1348.	1.6	20
391	Compelling Benefit of Soluble Suppression of Tumorigenicityâ€¢ in Postâ€“Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. Journal of the American Heart Association, 2017, 6, .	3.7	7
392	Colchicine in Pericarditis. European Heart Journal, 2017, 38, 1706-1709.	2.2	28
393	Biotherapies and biomarkers for cardiovascular diseases. European Heart Journal, 2017, 38, 1784-1786.	2.2	3
394	Preclinical Safety Evaluation of Allogeneic Induced Pluripotent Stem Cell-Based Therapy in a Swine Model of Myocardial Infarction. Tissue Engineering - Part C: Methods, 2017, 23, 736-744.	2.1	10
395	Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. Npj Systems Biology and Applications, 2017, 3, 12.	3.0	96
396	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	4.1	127

#	ARTICLE	IF	CITATIONS
397	Conservative management in very elderly patients with severe aortic stenosis: Time to change?. <i>Journal of Cardiology</i> , 2017, 69, 883-887.	1.9	7
398	Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing. <i>Stem Cells Translational Medicine</i> , 2017, 6, 647-655.	3.3	28
399	Electromechanical Conditioning of Adult Progenitor Cells Improves Recovery of Cardiac Function After Myocardial Infarction. <i>Stem Cells Translational Medicine</i> , 2017, 6, 970-981.	3.3	26
400	Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). <i>BMJ Open</i> , 2017, 7, e018719.	1.9	40
401	Prognostic Value of Newâ€“Generation Troponins in STâ€“Segmentâ€“Elevation Myocardial Infarction in the Modern Era: The RUTâ€“STEMI Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	16
402	Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. <i>Theranostics</i> , 2017, 7, 270-284.	10.0	155
403	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. <i>BMJ Open</i> , 2017, 7, e017187.	1.9	9
404	Mesenchymal Stem Cells Induce Expression of CD73 in Human Monocytes In Vitro and in a Swine Model of Myocardial Infarction In Vivo. <i>Frontiers in Immunology</i> , 2017, 8, 1577.	4.8	36
405	Global position paper on cardiovascular regenerative medicine. <i>European Heart Journal</i> , 2017, 38, 2532-2546.	2.2	133
406	Surface ECG interatrial block-guided treatment for stroke prevention: rationale for an attractive hypothesis. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 211.	1.7	28
407	A DAG-based comparison of interventional effect underestimation between composite endpoint and multi-state analysis in cardiovascular trials. <i>BMC Medical Research Methodology</i> , 2017, 17, 92.	3.1	8
408	Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?. <i>Stem Cell Research and Therapy</i> , 2017, 8, 238.	5.5	49
409	Inspiratory Muscle Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 480-484.	1.7	8
410	Highlights of the 2016 European Society of Cardiology Guidelines on Heart Failure. <i>European Cardiology Review</i> , 2017, 12, 76.	2.2	3
411	Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 37.	2.4	12
412	Putting Together the Pieces of the Natriuretic Peptide Puzzle â—-. <i>JACC: Heart Failure</i> , 2016, 4, 670-673.	4.1	5
413	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	7.1	49
414	Equalization of Intracardiac Pressures in Cardiac Tamponade. <i>Anesthesia and Analgesia</i> , 2016, 122, 959-962.	2.2	0

#	ARTICLE	IF	CITATIONS
415	Serum neprilysin and recurrent hospitalizations after acute heart failure. International Journal of Cardiology, 2016, 220, 742-744.	1.7	12
416	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2016, 18, 576-576.	7.1	4
417	Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients. JACC: Heart Failure, 2016, 4, 736-745.	4.1	11
418	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016, 27, 804-810.	1.7	38
419	Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovascular Diabetology, 2016, 15, 151.	6.8	51
420	What is on the horizon for improved treatments for acutely decompensated heart failure?. European Heart Journal Supplements, 2016, 18, G33-G42.	0.1	0
421	Weight Loss in Obese Patients With Heart Failure. Journal of the American Heart Association, 2016, 5, e002468.	3.7	59
422	¿Debemos anticoagular a pacientes en alto riesgo de sufrir fibrilación auricular?. Revista Espanola De Cardiologia, 2016, 69, 374-376.	1.2	28
423	A method to adapt thoracic impedance based on chest geometry and composition to assess congestion in heart failure patients. Medical Engineering and Physics, 2016, 38, 538-546.	1.7	8
424	Péptidos natriuréticos: consenso y uso necesarios. Revista Espanola De Cardiologia, 2016, 69, 817-819.	1.2	9
425	Reply to the Editorâ€”Prevalence of interatrial block during lifetime. Heart Rhythm, 2016, 13, e91.	0.7	1
426	Wearable vest for pulmonary congestion tracking and prognosis in heart failure: A pilot study. International Journal of Cardiology, 2016, 215, 77-79.	1.7	12
427	Concentraciones plasmáticas de neprilisina: un nuevo marcador pronóstico en la insuficiencia cardiaca. Revista Espanola De Cardiologia, 2016, 69, 535-536.	1.2	2
428	Neprilysin Plasma Concentrations: A New Prognostic Marker in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 535-536.	0.6	1
429	Soluble neprilysin retains catalytic activity in heart failure. Journal of Heart and Lung Transplantation, 2016, 35, 684-685.	0.6	23
430	Bayâ€sâ€™ Syndrome. Revista Espanola De Cardiologia (English Ed), 2016, 69, 439.	0.6	4
431	Cinética de la hemoglobina y pronóstico a largo plazo en insuficiencia cardiaca. Revista Espanola De Cardiologia, 2016, 69, 820-826.	1.2	13
432	Neprilisina: indicaciones, expectativas y retos. Revista Espanola De Cardiologia, 2016, 69, 647-649.	1.2	8

#	ARTICLE	IF	CITATIONS
433	A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function. JACC Basic To Translational Science, 2016, 1, 360-372.	4.1	20
434	A Test in Context: Neprilysin. Journal of the American College of Cardiology, 2016, 68, 639-653.	2.8	197
435	Cardiac Tissue Engineering. Journal of the American College of Cardiology, 2016, 68, 724-726.	2.8	7
436	Incidence and predictors of new-onset atrioventricular block requiring pacemaker implantation after sutureless aortic valve replacement. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 861-868.	1.1	29
437	Neprilysin: Indications, Expectations, and Challenges. Revista Espanola De Cardiologia (English Ed), 2016, 69, 647-649.	0.6	7
438	Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. European Journal of Internal Medicine, 2016, 35, 89-94.	2.2	68
439	Unraveling Myocardial Mass. Journal of the American College of Cardiology, 2016, 68, 1449-1451.	2.8	1
440	Brilliant violet fluorochromes in simultaneous multicolor flow cytometryâ€“fluorescence in situ hybridization measurement of monocyte subsets and telomere length in heart failure. Laboratory Investigation, 2016, 96, 1223-1230.	3.7	3
441	Analysis of blood pressure signal in patients with different ventricular ejection fraction using linear and non-linear methods. , 2016, 2016, 2700-2703.		3
442	Biomarkers in Heart Failure: ST2., 2016, , 251-268.		0
443	ST2-Based Precision Medicine in Device Management: the Next Frontier Beyond MADIT-CRT?. Journal of Cardiovascular Translational Research, 2016, 9, 419-420.	2.4	0
444	Quality and exploitation of umbilical cord blood for cell therapy: Are we beyond our capabilities?. Developmental Dynamics, 2016, 245, 710-717.	1.8	6
445	Bioelectrical impedance vector analysis and clinical outcomes in patients with acute heart failure. Journal of Cardiovascular Medicine, 2016, 17, 283-290.	1.5	26
446	Neprilysin and Natriuretic Peptide Regulation in Heart Failure. Current Heart Failure Reports, 2016, 13, 151-157.	3.3	31
447	Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 820-826.	0.6	7
448	Revista EspaÃ±ola de CardiologÃ¡a: Current Position and Future Directions. Revista Espanola De Cardiologia (English Ed), 2016, 69, 327-336.	0.6	3
449	Natriuretic Peptides: Consensus Call for Use. Revista Espanola De Cardiologia (English Ed), 2016, 69, 817-819.	0.6	3
450	First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar. EBioMedicine, 2016, 7, 248-254.	6.1	12

#	ARTICLE	IF	CITATIONS
451	Minimally invasive diagnosis of a pericardial mass by CT-guided fine-needle aspiration. <i>Cardiovascular Pathology</i> , 2016, 25, 275-279.	1.6	1
452	Three-Dimensional Cultures of Human Subcutaneous Adipose Tissue-Derived Progenitor Cells Based on RAD16-I Self-Assembling Peptide. <i>Tissue Engineering - Part C: Methods</i> , 2016, 22, 113-124.	2.1	17
453	The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. <i>Biomarkers</i> , 2016, 21, 225-232.	1.9	9
454	Naming and classifying old and new ECG phenomena. <i>Cmaj</i> , 2016, 188, 485-486.	2.0	9
455	Circulating Endothelial Progenitor Cells: Potential Biomarkers for Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 80-84.	2.4	11
456	Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: <i>in situ</i> fibrinolysis vs. percutaneous coronary intervention transfer. <i>European Heart Journal</i> , 2016, 37, 1034-1040.	2.2	41
457	SÀndrome de BayÀ@s. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 439.	1.2	5
458	Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 204, 242-247.	1.7	26
459	Should We Anticoagulate Patients at High Risk of Atrial Fibrillation?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 374-376.	0.6	24
460	Worsening Renal Function in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 232-233.	4.1	4
461	Interatrial block and atrial arrhythmias in centenarians: Prevalence, associations, and clinical implications. <i>Heart Rhythm</i> , 2016, 13, 645-651.	0.7	93
462	Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 249-255.	1.7	31
463	Can Natriuretic Peptides be Used to Guide Therapy?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 208-16.	0.7	9
464	Cardiorespiratory and cardiovascular interactions in cardiomyopathy patients using joint symbolic dynamic analysis. , 2015, 2015, 306-9.		4
465	In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changinâ€™. <i>Stem Cell Research and Therapy</i> , 2015, 6, 248.	5.5	55
466	Challenging the two concepts in determining the appropriate preâ€¢discharge Nâ€¢terminal proâ€¢brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?. <i>European Journal of Heart Failure</i> , 2015, 17, 936-944.	7.1	30
467	Preclinical Evaluation of the Immunomodulatory Properties of Cardiac Adipose Tissue Progenitor Cells Using Umbilical Cord Blood Mesenchymal Stem Cells: A Direct Comparative Study. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	21
468	Impact of Umbilical Cord Blood-Derived Mesenchymal Stem Cells on Cardiovascular Research. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	13

#	ARTICLE	IF	CITATIONS
469	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.	2.2	53
470	Aging and Heart Rate in Heart Failure: Clinical Implications for Long-term Mortality. Mayo Clinic Proceedings, 2015, 90, 765-772.	3.0	12
471	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. International Journal of Cardiology, 2015, 184, 337-343.	1.7	92
472	The role and potential of umbilical cord blood in an era of new therapies: a review. Stem Cell Research and Therapy, 2015, 6, 123.	5.5	85
473	Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts. Stem Cell Research and Therapy, 2015, 6, 108.	5.5	41
474	Reduced Irregularity of Ventricular Response During Atrial Fibrillation and Long-term Outcome in Patients With Heart Failure. American Journal of Cardiology, 2015, 116, 1071-1075.	1.6	28
475	Validació de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. Revista Espanola De Cardiologia, 2015, 68, 80-81.	1.2	4
476	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a Cohort From Boston. Revista Espanola De Cardiologia (English Ed), 2015, 68, 80-81.	0.6	3
477	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Illinois, Estados Unidos, 15-19 de noviembre de 2014). Revista Espanola De Cardiologia, 2015, 68, 145.e1-145.e8.	1.2	0
478	ST2 and Multimarker Testing in Acute Decompensated Heart Failure. American Journal of Cardiology, 2015, 115, 38B-43B.	1.6	21
479	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. Journal of Cardiac Failure, 2015, 21, 355-361.	1.7	31
480	ST2 and Patient Prognosis in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 64B-69B.	1.6	53
481	To the Editor: Interatrial block: Another risk to take into account after radiofrequency ablation of typical atrial flutter. Heart Rhythm, 2015, 12, e119-e120.	0.7	0
482	Soluble Neprilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. Journal of the American College of Cardiology, 2015, 65, 657-665.	2.8	137
483	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, Illinois, United States, November 15-19, 2014). Revista Espanola De Cardiologia (English Ed), 2015, 68, 145.e1-145.e8.	0.6	0
484	New-onset atrial fibrillation after cavotricuspid isthmus ablation: identification of advanced interatrial block is key. Europace, 2015, 17, 1289-1293.	1.7	84
485	Structural Heart Disease and ST2: Cross-Sectional and Longitudinal Associations With Echocardiography. American Journal of Cardiology, 2015, 115, 59B-63B.	1.6	30
486	Differential Diagnosis of rSr Pattern in Leads V ₁ -V ₂ . Comprehensive Review and Proposed Algorithm. , 2015, 20, 7-17.		35

#	ARTICLE	IF	CITATIONS
487	Body mass index, body fat, and nutritional status of patients with heart failure: The PLICA study. Clinical Nutrition, 2015, 34, 1233-1238.	5.0	42
488	Multimarker Testing With ST2 in Chronic Heart Failure. American Journal of Cardiology, 2015, 115, 76B-80B.	1.6	19
489	Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty. International Journal of Cardiology, 2015, 198, 70-74.	1.7	13
490	Neprilysin in Heart Failure. JACC: Heart Failure, 2015, 3, 637-640.	4.1	23
491	Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry. Revista Espanola De Cardiologia (English Ed), 2015, 68, 785-793.	0.6	21
492	Hypoxia-driven sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) downregulation depends on low-density lipoprotein receptor-related protein 1 (LRP1)-signalling in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2015, 85, 25-36.	1.9	18
493	The International ST2 Consensus Panel: Introduction. American Journal of Cardiology, 2015, 115, 1B-2B.	1.6	4
494	Fate of Original Articles Rejected by Revista EspaÑola de CardiologÃa. Revista Espanola De Cardiologia (English Ed), 2015, 68, 263-264.	0.6	0
495	Acute Heart Failure: The Unrecognized Epidemic. Revista Espanola De Cardiologia (English Ed), 2015, 68, 243-244.	0.6	0
496	2014 Annual Summary and New Projects in Revista EspaÑola de CardiologÃa. Revista Espanola De Cardiologia (English Ed), 2015, 68, 265-272.	0.6	1
497	Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels. Reply. International Journal of Cardiology, 2015, 190, 201.	1.7	0
498	Anti-Ro/SSA antibodies and cardiac rhythm disturbances: Present and future perspectives. International Journal of Cardiology, 2015, 184, 244-250.	1.7	15
499	Answer. Reverse remodeling in systolic heart failure. The ST2-R2 score: a puzzle yet to be solved?. International Journal of Cardiology, 2015, 187, 556.	1.7	0
500	Destino de los artÃculos originales rechazados en Revista EspaÑola de CardiologÃa. Revista Espanola De Cardiologia, 2015, 68, 263-264.	1.2	4
501	Risk Prediction Tools in Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 267.	4.1	8
502	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1075-1084.	0.6	23
503	Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 641-644.	4.1	44
504	AdecuaciÃ³n en EspaÑa a las recomendaciones terapÃ©uticas de la ESC sobre insuficiencia cardiaca: ESC Heart Failure Long-term Registry. Revista Espanola De Cardiologia, 2015, 68, 785-793.	1.2	64

#	ARTICLE	IF	CITATIONS
505	From Atrial Fibrillation to Ventricular Fibrillation and Back. <i>Circulation</i> , 2015, 132, 2035-2036.	1.6	2
506	Postinfarction Functional Recovery Driven by a Three-Dimensional Engineered Fibrin Patch Composed of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. <i>Stem Cells Translational Medicine</i> , 2015, 4, 956-966.	3.3	39
507	Impassable brachiocephalic tortuosity in right transradial access: Overcoming the curves with the pigtail catheter. <i>International Journal of Cardiology</i> , 2015, 180, 76-77.	1.7	0
508	Multiple biomarker strategies for risk stratification in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 120-125.	1.1	25
509	In vitro comparative study of two decellularization protocols in search of an optimal myocardial scaffold for recellularization. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 558-73.	0.0	37
510	Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN) Tj ETQqO 0 0 rgBT /Overlock 10 Tf ₂₅		
511	Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C. <i>Clinical Chemistry</i> , 2014, 60, 481-489.	3.2	28
512	Renal function largely influences Galectin-3 prognostic value in heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 171-177.	1.7	52
513	Formació n mÁ dica continuada: un objetivo prioritario en Revista Espáola de Cardiología. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 1068-1073.	1.2	5
514	Umbilical cord blood-derived mesenchymal stem cells: New therapeutic weapons for idiopathic dilated cardiomyopathy?. <i>International Journal of Cardiology</i> , 2014, 177, 809-818.	1.7	16
515	Continuing Medical Education: A Priority in Revista Espáola de Cardiología. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 1068-1073.	0.6	1
516	Using ST2 in cardiovascular patients: a review. <i>Future Cardiology</i> , 2014, 10, 525-539.	1.2	59
517	Microwave spectrometry for the evaluation of the structural integrity of metallic stents. <i>Medical Physics</i> , 2014, 41, 041902.	3.0	7
518	RF monitoring of commercial vascular stents with dipole scattering resonances. , 2014, , .		1
519	Physiological conditioning by electric field stimulation promotes cardiomyogenic gene expression in human cardiomyocyte progenitor cells. <i>Stem Cell Research and Therapy</i> , 2014, 5, 93.	5.5	23
520	Educational level and self-care behaviour in patients with heart failure before and after nurse educational intervention. <i>European Journal of Cardiovascular Nursing</i> , 2014, 13, 459-465.	0.9	28
521	Thrombus age, clinical presentation, and reperfusion grade in myocardial infarction. <i>Cardiovascular Pathology</i> , 2014, 23, 126-130.	1.6	17
522	SÁndromes coronarios agudos: nuevas estrategias de diagnÓstico y tratamiento. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 138.	1.2	5

#	ARTICLE	IF	CITATIONS
523	Results of Primary Percutaneous Coronary Intervention in Patients ≥ 75 Years Treated by the Transradial Approach. <i>American Journal of Cardiology</i> , 2014, 113, 452-456.	1.6	15
524	Chronobiology of Death in Heart Failure. <i>Revista Espanola De Cardiologia</i> (English Ed), 2014, 67, 387-393.	0.6	3
525	Acute Coronary Syndromes. New Diagnostic Strategies and Treatment. <i>Revista Espanola De Cardiologia</i> (English Ed), 2014, 67, 138.	0.6	4
526	Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2014, 63, 158-166.	2.8	222
527	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2014 (August 30 – September 3, 2014, Barcelona, Spain). <i>Revista Espanola De Cardiologia</i> (English Ed), 2014, 67, 912.e1-912.e10.	0.6	0
528	Is Cocaine-associated Acute Myocardial Infarction the Same as Myocardial Infarction Associated With Recent Cocaine Consumption?. <i>Revista Espanola De Cardiologia</i> (English Ed), 2014, 67, 964-965.	0.6	0
529	To the Editorâ€” Interatrial block and atrial fibrillation: Invasive and noninvasive measurements may help to define the syndrome. <i>Heart Rhythm</i> , 2014, 11, e197-e198.	0.7	3
530	Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality. <i>International Journal of Cardiology</i> , 2014, 177, 209-210.	1.7	9
531	Resumen de estudios clÃ¡nicos presentados en el Congreso de 2014 de la Sociedad Europea de CardiologÃa (30 de agosto-3 de septiembre de 2014, Barcelona, EspaÃ±a). <i>Revista Espanola De Cardiologia</i> , 2014, 67, 912.e1-912.e10.	1.2	5
532	Â¿Los trastornos por cocaÃ±a asociados al infarto agudo de miocardio son lo mismo que el infarto de miocardio asociado al consumo reciente de cocaÃ±a?. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 964-965.	1.2	0
533	Allogeneic adipose stem cell therapy in acute myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2014, 44, 83-92.	3.4	47
534	A novel wearable vest for tracking pulmonary congestion in acutely decompensated heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 199-201.	1.7	28
535	A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: Â‰LAN-HF Score. <i>Heart</i> , 2014, 100, 115-125.	2.9	106
536	Comparison of two preclinical myocardial infarct models: coronary coil deployment versus surgical ligation. <i>Journal of Translational Medicine</i> , 2014, 12, 137.	4.4	22
537	Comments on the Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Response. <i>Revista Espanola De Cardiologia</i> (English Ed), 2014, 67, 158-159.	0.6	0
538	Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: Potential impact in ventricular remodeling. <i>International Journal of Cardiology</i> , 2014, 176, 805-814.	1.7	21
539	Autoimmunity and Atrioventricular Block of Unknown Etiology in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1335-1336.	2.8	12
540	Fragility is a key determinant of survival in heart failure patients. <i>International Journal of Cardiology</i> , 2014, 175, 62-66.	1.7	45

#	ARTICLE	IF	CITATIONS
541	Do Inappropriate Implantable Cardioverter-defibrillator Shocks Generate Additional Costs?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 65-66.	0.6	1
542	Online monitoring of myocardial bioprostheses for cardiac repair. International Journal of Cardiology, 2014, 174, 654-661.	1.7	34
543	Optimal decongestive therapy in acute decompensated heart failure syndromes: Far from being solved. International Journal of Cardiology, 2014, 174, 457-458.	1.7	1
544	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Washington D.C., Estados Unidos, 29-31 de marzo de 2014). Revista Espanola De Cardiologia, 2014, 67, 479.e1-479.e7.	1.2	22
545	Prognostic value of increased carbohydrate antigen in patients with heart failure. World Journal of Cardiology, 2014, 6, 205.	1.5	8
546	Engineered 3D bioimplants using elastomeric scaffold, self-assembling peptide hydrogel, and adipose tissue-derived progenitor cells for cardiac regeneration. American Journal of Translational Research (discontinued), 2014, 6, 291-301.	0.0	24
547	Resumen de estudios clínicos presentados en el Congreso de 2013 de la Sociedad Europea de Cardiología (31 de agosto-4 de septiembre de 2013, Ámsterdam, Países Bajos). Revista Espanola De Cardiologia, 2013, 66, 879.e1-879.e9.	1.2	9
548	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2013 (31) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	0
549	Revista Española de Cardiología, siguiendo el pulso de la era digital. Revista Espanola De Cardiologia, 2013, 66, 996-998.	1.2	8
550	Depression, antidepressants, and long-term mortality in heart failure. International Journal of Cardiology, 2013, 167, 1217-1225.	1.7	62
551	Integration of a local into a regional primary angioplasty action plan (the Catalan Codi Infart) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	1.7	10
552	Self-management of Vitamin K Antagonists Is More Cost-effective Than Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain. Revista Espanola De Cardiologia (English Ed), 2013, 66, 510-511.	0.6	0
553	Cardiac Tissue Engineering and the Bioartificial Heart. Revista Espanola De Cardiologia (English Ed), 2013, 66, 391-399.	0.6	39
554	Advanced interatrial block: a well-defined electrocardiographic pattern with clinical arrhythmological implications. Europace, 2013, 15, 1822-1822.	1.7	8
555	The Challenges for Cardiac Vascular Precursor Cell Therapy: Lessons from a Very Elusive Precursor. Journal of Vascular Research, 2013, 50, 304-323.	1.4	15
556	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Los Angeles, CA, USA, november 3-7, 2012). Revista Espanola De Cardiologia (English Ed), 2013, 66, 55.e1-55.e11.	0.6	0
557	Cardiac adipose tissue: A new frontier for cardiac regeneration?. International Journal of Cardiology, 2013, 167, 22-25.	1.7	25
558	Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. European Journal of Heart Failure, 2013, 15, 103-109.	7.1	42

#	ARTICLE	IF	CITATIONS
559	Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment. <i>Mayo Clinic Proceedings</i> , 2013, 88, 234-243.	3.0	57
560	Soluble ST2 Serum Concentration and Renal Function in Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 768-775.	1.7	87
561	The obesity paradox in heart failure: Is etiology a key factor?. <i>International Journal of Cardiology</i> , 2013, 166, 601-605.	1.7	52
562	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (San Francisco, California, Estados Unidos, 8-12 de marzo de 2013). <i>Revista Española De Cardiología</i> , 2013, 66, 482.e1-482.e8.	1.2	9
563	Spironolactone in mild chronic heart failure: Insights from a propensity-matched analysis of the MUSIC study cohort. <i>International Journal of Cardiology</i> , 2013, 168, 4525-4527.	1.7	3
564	Transradial percutaneous coronary intervention in cardiogenic shock: A single-center experience. <i>American Heart Journal</i> , 2013, 165, 280-285.	2.7	34
565	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Los Ángeles, California, Estados Unidos, 3-7 de noviembre de 2012). <i>Revista Española De Cardiología</i> , 2013, 66, 55.e1-55.e11.	1.2	17
566	Resumen anual y novedades del año 2012 en REVISTA ESPAÑOLA DE CARDIOLOGÍA. <i>Revista Española De Cardiología</i> , 2013, 66, 231-240.	1.2	6
567	Ingeniería tisular cardiaca y corazón bioartificial. <i>Revista Española De Cardiología</i> , 2013, 66, 391-399.	1.2	45
568	Bioluminescence imaging: a shining future for cardiac regeneration. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 693-703.	3.6	31
569	Creating the bioartificial myocardium for cardiac repair: challenges and clinical targets. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1701-1711.	1.5	20
570	Innovación en cardiología: introducción. <i>Revista Española De Cardiología</i> , 2013, 66, 133.	1.2	13
571	Bioluminescence imaging of cardiomyogenic and vascular differentiation of cardiac and subcutaneous adipose tissue-derived progenitor cells in fibrin patches in a myocardium infarct model. <i>International Journal of Cardiology</i> , 2013, 169, 288-295.	1.7	33
572	Análisis de la demanda telefónica en una unidad de insuficiencia cardiaca: motivos de consulta y utilización de recursos. <i>Revista Española De Cardiología</i> , 2013, 66, 914-915.	1.2	7
573	New insights into lipid raft function regulating myocardial vascularization competency in human idiopathic dilated cardiomyopathy. <i>Atherosclerosis</i> , 2013, 230, 354-364.	0.8	7
574	Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. <i>Clinica Chimica Acta</i> , 2013, 426, 18-24.	1.1	34
575	Effect of Fragility on Quality of Life in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 1785-1789.	1.6	22
576	Post-infarction scar coverage using a pericardial-derived vascular adipose flap. Pre-clinical results. <i>International Journal of Cardiology</i> , 2013, 166, 469-474.	1.7	23

#	ARTICLE	IF	CITATIONS
577	Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Revista Espanola De Cardiologia (English Ed), 2013, 66, 914-915.	0.6	0
578	2012 Annual Summary and New Projects in Revista EspaÑola de CardiologÃa. Revista Espanola De Cardiologia (English Ed), 2013, 66, 231-240.	0.6	4
579	Innovation in Cardiology: Introduction. Revista Espanola De Cardiologia (English Ed), 2013, 66, 133.	0.6	1
580	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American College of Cardiology (San Francisco, CA, United States, March 8-12, 2013). Revista Espanola De Cardiologia (English Ed), 2013, 66, 482.e1-482.e8.	0.6	0
581	Revista EspaÑola de CardiologÃa: Keeping Its Finger on the Pulse of the Digital Age. Revista Espanola De Cardiologia (English Ed), 2013, 66, 996-998.	0.6	5
582	Hypoxia Induces Metalloproteinase-9 Activation and Human Vascular Smooth Muscle Cell Migration Through Low-Density Lipoprotein Receptor-Related Protein 1-Mediated Pyk2 Phosphorylation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2877-2887.	2.4	34
583	Anti-Ro Antibodies and Reversible Atrioventricular Block. New England Journal of Medicine, 2013, 368, 2335-2337.	27.0	30
584	Statins in heart failure: not yet the end of the story?. European Journal of Heart Failure, 2013, 15, 708-709.	7.1	4
585	Pseudoatrial Fibrillation during Pacemaker Interrogation: What is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 695-698.	1.2	0
586	Identification of Temporal and Region-Specific Myocardial Gene Expression Patterns in Response to Infarction in Swine. PLoS ONE, 2013, 8, e54785.	2.5	32
587	The utility of stent enhancement to guide percutaneous coronary intervention for bifurcation lesions. EurolIntervention, 2013, 9, 968-974.	3.2	10
588	Acute Coronary Syndromes in 2011 and 2012. Arquivos Brasileiros De Cardiologia, 2013, 101, 473.	0.8	0
589	CardioPulse: additional history on myocardial infarction, from the seventeenth century to the present. European Heart Journal, 2013, 34, 1614.	2.2	0
590	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 309-314.	3.9	152
591	Low Atrial Fibrillatory Rate Is Associated With Poor Outcome in Patients With Mild to Moderate Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 77-83.	4.8	17
592	Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. European Journal of Heart Failure, 2012, 14, 32-38.	7.1	130
593	Evaluation of a telemedicine system for heart failure patients: feasibility, acceptance rate, satisfaction and changes in patient behavior: results from the CARME (CATalan Remote Management Evaluation) study. European Journal of Cardiovascular Nursing, 2012, 11, 410-418.	0.9	28
594	CardioPulse Articles. European Heart Journal, 2012, 33, 2883-2891.	2.2	3

#	ARTICLE	IF	CITATIONS
595	Fetal-maternal interface: A chronicle of allogeneic coexistence. <i>Chimerism</i> , 2012, 3, 18-23.	0.7	5
596	Predictive Value of Beat-to-Beat QT Variability Index Across the Continuum of Left Ventricular Dysfunction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 719-727.	4.8	51
597	Undernourishment and Prognosis in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 196-197.	0.6	1
598	Arrhythmias: Introduction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 91.	0.6	0
599	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Orlando, United States, November 12-16, 2011). <i>Revista Espanola De Cardiologia (English Ed)</i>	0.784	014 rgBT/0
600	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American College of Cardiology (Chicago, Illinois, United States, March 24-27, 2012). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 559.e1-559.e8.	0.6	0
601	Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. <i>Mayo Clinic Proceedings</i> , 2012, 87, 555-560.	3.0	55
602	Average T-wave alternans activity in ambulatory ECG records predicts sudden cardiac death in patients with chronic heart failure. <i>Heart Rhythm</i> , 2012, 9, 383-389.	0.7	38
603	DesnutriciÃ³n y pronÃ³stico en insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 196-197.	1.2	3
604	Arritmias: IntroducciÃ³n. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 91.	1.2	10
605	Resumen de los ensayos clÃ¡nicos presentados en las Sesiones CientÃ¢ficas Anuales de la American Heart Association (Orlando, Estados Unidos, 12-16 de noviembre de 2011). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 71.e1-71.e9.	1.2	6
606	Resumen de los ensayos clÃ¡nicos presentados en las Sesiones CientÃ¢ficas Anuales del American College of Cardiology (Chicago, Illinois, Estados Unidos, 24-27 de marzo de 2012). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 559.e1-559.e8.	1.2	10
607	Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. <i>American Heart Journal</i> , 2012, 163, 821-828.	2.7	54
608	Estimated Glomerular Filtration Rate and Prognosis in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1709-1715.	2.8	121
609	TCT-405 Transradial approach decreases in-hospital mortality in patients with cardiogenic shock. A single-center experience. <i>Journal of the American College of Cardiology</i> , 2012, 60, B116.	2.8	0
610	Interatrial blocks. A separate entity from left atrial enlargement: a consensus report. <i>Journal of Electrocardiology</i> , 2012, 45, 445-451.	0.9	292
611	Letter to the Editor: "Average T-wave alternans activity in ambulatory electrocardiogram records: Commentary on the relationship with T-wave amplitude and T-wave alternans regionality. <i>Heart Rhythm</i> , 2012, 9, e6-e7.	0.7	0
612	Resumen de estudios clÃ¡nicos presentados en el Congreso de 2012 de la Sociedad Europea de CardiologÃa (25-29 de agosto de 2012, MÃnich, Alemania). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 1018.e1-1018.e8.	1.2	10

#	ARTICLE	IF	CITATIONS
613	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2012 (August 25-29, 2012, Munich, Germany). Revista Espanola De Cardiologia (English Ed), 2012, 65, 1018.e1-1018.e8.	0.6	0
614	Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification. PLoS ONE, 2012, 7, e51234.	2.5	14
615	Umbilical cord blood for cardiovascular cell therapy: from promise to fact. Annals of the New York Academy of Sciences, 2012, 1254, 66-70.	3.8	22
616	A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration. Annals of the New York Academy of Sciences, 2012, 1254, 57-65.	3.8	48
617	Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Promote Vascular Growth In Vivo. PLoS ONE, 2012, 7, e49447.	2.5	70
618	Safety and efficacy of transradial access in coronary angiography: 8-year experience. Journal of Invasive Cardiology, 2012, 24, 346-51.	0.4	9
619	Systemic Diseases and the Cardiovascular System: Introduction. Revista Espanola De Cardiologia (English Ed), 2011, 64, 60-61.	0.6	6
620	Obesity paradox and risk of sudden death in heart failure. American Heart Journal, 2011, 161, 158-164.	2.7	30
621	Optimizing electrocardiographic interpretation in acute ST-elevation myocardial infarction may be very beneficial. American Heart Journal, 2011, 162, e1-e2.	2.7	15
622	Negative Clinical Outcomes Associated With Drug-Related Problems in Heart Failure (HF) Outpatients: Impact of a Pharmacist in a Multidisciplinary HF Clinic. Journal of Cardiac Failure, 2011, 17, 217-223.	1.7	76
623	Bioelectrical impedance vector analysis (BIVA) in stable and non-stable heart failure patients: A pilot study. International Journal of Cardiology, 2011, 146, 262-264.	1.7	22
624	Hypoxia exacerbates Ca2+-handling disturbances induced by very low density lipoproteins (VLDL) in neonatal rat cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2011, 50, 894-902.	1.9	25
625	Enfermedades sistémicas y corazón: introducción. Revista Espanola De Cardiologia, 2011, 64, 60-61.	1.2	10
626	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Estados Unidos, 13-17 de noviembre de 2010). Revista Espanola De Cardiologia, 2011, 64, 59.e1-59.e8.	1.2	15
627	Telemonitorización no invasiva en pacientes con insuficiencia cardíaca y servicios de urgencias hospitalarios. Respuesta. Revista Espanola De Cardiologia, 2011, 64, 949.	1.2	0
628	Resumen de estudios clínicos presentados en el Congreso de 2011 de la European Society of Cardiology (27-30 de agosto de 2011, París, Francia). Revista Espanola De Cardiologia, 2011, 64, 1011.e1-1011.e8.	1.2	14
629	Noninvasive Remote Telemonitoring for Ambulatory Patients With Heart Failure: Effect on Number of Hospitalizations, Days in Hospital, and Quality of Life. CARME (CATalan Remote Management) Tj ETQq1 1 0.784314rgBT /Overlock 10 T		
630	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, United States, November 13-17, 2010). Revista Espanola De Cardiología (English Ed) Tj ETQq0.0 0 rgBT/Overlock		

#	ARTICLE	IF	CITATIONS
631	New Statistical Methods in Cardiovascular Research. <i>Revista Espanola De Cardiologia</i> (English Ed), 2011, 64, 499-500.	0.6	4
632	Analysis of Reperfusion Delay in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty Based on First Medical Contact and Time of Presentation. <i>Revista Espanola De Cardiologia</i> (English Ed), 2011, 64, 476-483.	0.6	2
633	Noninvasive Remote Telemonitoring for Ambulatory Patients With Heart Failure and Emergency Department Services. <i>Revista Espanola De Cardiologia</i> (English Ed), 2011, 64, 949.	0.6	0
634	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2011 (August 27-30, 2011, Paris, France). <i>Revista Espanola De Cardiologia</i> (English Ed), 2011, 64, 1011.e1-1011.e8.	0.6	0
635	2011 Annual Summary. Another Meeting With Our Readers. <i>Revista Espanola De Cardiologia</i> (English Ed) Tj ETQq1_0.7843_14 rgBT /Ov	0.6	0
636	Usefulness of Body Mass Index to Characterize Nutritional Status in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 1166-1170.	1.6	56
637	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. <i>Annals of Thoracic Surgery</i> , 2011, 92, 2118-2124.	1.3	41
638	Transposition of a pericardial-derived vascular adipose flap for myocardial salvage after infarct. <i>Cardiovascular Research</i> , 2011, 91, 659-667.	3.8	34
639	Acute coronary syndrome and cocaine use: 8-year prevalence and inhospital outcomes. <i>European Heart Journal</i> , 2011, 32, 1244-1250.	2.2	53
640	Exposure to cardiomyogenic stimuli fails to transdifferentiate human umbilical cord blood-derived mesenchymal stem cells. <i>Basic Research in Cardiology</i> , 2010, 105, 419-430.	5.9	41
641	Impact of Kidney Dysfunction on Plasma and Urinary N-terminal Pro-B-type Natriuretic Peptide in Patients With Acute Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 214-220.	2.0	34
642	Hyponatremia, Natriuretic Peptides, and Outcomes in Acutely Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 354-361.	3.9	53
643	New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. <i>Biomarkers</i> , 2010, 15, 307-314.	1.9	16
644	A New Editorial Phase With New Projects. <i>Revista Espanola De Cardiologia</i> (English Ed), 2010, 63, 865-868.	0.6	0
645	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. <i>Revista Espanola De Cardiologia</i> (English Ed), 2010, 63, 1171-1178.	0.6	31
646	Obesity and Long-Term Prognosis in Heart Failure: the Paradox Persists. <i>Revista Espanola De Cardiologia</i> (English Ed), 2010, 63, 1210-1211.	0.6	3
647	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2010 (August 28-September 1, 2010, Stockholm, Sweden). <i>Revista Espanola De Cardiologia</i> (English Ed), 2010, 63, 1292-1303.	0.6	10
648	Annual Summary 2010: Bibliometric Data, Activities, and New Production of the Journal. <i>Revista Espanola De Cardiologia</i> (English Ed), 2010, 63, 1501-1509.	0.6	4

#	ARTICLE	IF	CITATIONS
649	Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of Administration. <i>Journal of Cardiac Failure</i> , 2010, 16, 357-366.	1.7	77
650	Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 771-780.	1.9	104
651	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando, Estados Unidos, 14-18 de noviembre de 2009). <i>Revista Española De Cardiología</i> , 2010, 63, 190-199.	1.2	24
652	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Atlanta, Estados Unidos, 14-16 de marzo de 2010). <i>Revista Española De Cardiología</i> , 2010, 63, 695-707.	1.2	19
653	Nueva etapa editorial y nuevos proyectos. <i>Revista Española De Cardiología</i> , 2010, 63, 865-868.	1.2	9
654	Obesidad y pronóstico a largo plazo en la insuficiencia cardiaca: la paradoja continúa. <i>Revista Española De Cardiología</i> , 2010, 63, 1210-1212.	1.2	10
655	Resumen anual año 2010: datos bibliométricos, actividades y nueva producción de la Revista. <i>Revista Española De Cardiología</i> , 2010, 63, 1501-1509.	1.2	9
656	Resumen de estudios clínicos presentados en el Congreso de 2010 de la European Society of Cardiology (28 de agosto-1 de septiembre de 2010, Estocolmo, Suecia). <i>Revista Española De Cardiología</i> , 2010, 63, 1292-1303.	1.2	21
657	Unplanned redundant publication: a consequence of too many cardiovascular journals?. <i>EuroIntervention</i> , 2010, 6, 179-181.	3.2	4
658	Comment on 'œs bioelectrical impedance vector analysis of value in the elderly with malnutrition and impaired functionality'â€. <i>Nutrition</i> , 2009, 25, 370-371.	2.4	3
659	Risk Stratification of Mortality in Patients With Heart Failure and Left Ventricular Ejection Fraction >35%. <i>American Journal of Cardiology</i> , 2009, 103, 1003-1010.	1.6	53
660	A New Electrocardiographic Algorithm to Locate the Occlusion in Left Anterior Descending Coronary Artery. <i>Clinical Cardiology</i> , 2009, 32, E1-6.	1.8	32
661	Predictors and Ramifications of Worsening Renal Function in Acutely Destabilized Heart Failure: Results from the ICON Study. <i>Journal of Cardiac Failure</i> , 2009, 15, S20-S21.	1.7	0
662	What Predicts Troponin Release in Acutely Decompensated Heart Failure?. <i>Journal of Cardiac Failure</i> , 2009, 15, S21.	1.7	0
663	Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2174-2179.	2.8	205
664	Orthotopic Heart Transplantation in Patients With Transposition of the Great Arteries. <i>Revista Española De Cardiología</i> (English Ed), 2009, 62, 216-219.	0.6	0
665	The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. <i>European Heart Journal</i> , 2009, 30, 1088-1096.	2.2	194
666	Vascular dysfunction in idiopathic dilated cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2009, 6, 590-598.	13.7	79

#	ARTICLE	IF	CITATIONS
667	Evolution of amino-terminal Pro-B type natriuretic peptide testing in heart failure. Drug News and Perspectives, 2009, 22, 267.	1.5	9
668	Prognostic Value of QT/RR Slope in Predicting Mortality in Patients with Congestive Heart Failure. Journal of Cardiovascular Electrophysiology, 2008, 19, 1066-1072.	1.7	39
669	Understanding Amino-Terminal Pro-B-Type Natriuretic Peptide in Obesity. American Journal of Cardiology, 2008, 101, S89-S94.	1.6	50
670	New electrocardiographic diagnostic criteria for the pathologic R waves in leads V1 and V2 of anatomically lateral myocardial infarction. Journal of Electrocardiology, 2008, 41, 413-418.	0.9	29
671	Association of Blood Pressure and Its Evolving Changes With the Survival of Patients With Heart Failure. Journal of Cardiac Failure, 2008, 14, 561-568.	1.7	16
672	Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. European Heart Journal, 2008, 29, 1011-1018.	2.2	71
673	Changes in myocardial electrical impedance in human heart graft rejection. European Journal of Heart Failure, 2008, 10, 594-600.	7.1	14
674	Characterization of periodic and non-periodic breathing pattern in chronic heart failure patients. , 2008, 2008, 3227-30.		5
675	Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. European Journal of Heart Failure, 2007, 9, 995-1002.	7.1	51
676	Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. European Journal of Heart Failure, 2007, 9, 802-807.	7.1	42
677	Hypertrophy and inflammation: too much for one heart. European Heart Journal, 2007, 28, 661-663.	2.2	10
678	B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans. Heart, 2007, 93, 1077-1080.	2.9	9
679	Reply: Does the adenosine A2A receptor stimulate the ryanodine receptor?. Cardiovascular Research, 2007, 73, 249-250.	3.8	2
680	Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure. Clinica Chimica Acta, 2007, 381, 145-150.	1.1	35
681	Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. International Journal of Cardiology, 2007, 120, 338-343.	1.7	36
682	Chimerism and microchimerism of the human heart: evidence for cardiac regeneration. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, S40-S45.	3.3	26
683	FGF-4 increases <i>in vitro</i> expansion rate of human adult bone marrow-derived mesenchymal stem cells. Growth Factors, 2007, 25, 71-76.	1.7	47
684	Detection and Quantification of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Contrast-Enhanced Cardiovascular Magnetic Resonance. Revista Espanola De Cardiologia (English Ed) Tj ETQq0 0 000gBT /Overlock 10 Tf		

#	ARTICLE	IF	CITATIONS
685	Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-“Brain Natriuretic Peptide in Patients With Acute Dyspnea. Archives of Internal Medicine, 2007, 167, 400.	3.8	125
686	NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. European Heart Journal, 2006, 27, 330-337.	2.2	978
687	Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1621-1627.	2.8	136
688	Usefulness of Intermediate Amino-Terminal Pro-Brain Natriuretic Peptide Concentrations for Diagnosis and Prognosis of Acute Heart Failure. American Journal of Cardiology, 2006, 98, 386-390.	1.6	103
689	Transient biventricular dysfunction following pericardiocentesis. European Journal of Heart Failure, 2006, 8, 102-104.	7.1	36
690	Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. Cardiovascular Research, 2006, 72, 292-302.	3.8	62
691	Effect of aging on the pluripotential capacity of human CD105+mesenchymal stem cells. European Journal of Heart Failure, 2006, 8, 555-563.	7.1	99
692	Plasma NT-proBNP: a new biomarker for diagnosis and monitoring of congestive heart failure (CHF). Timely Topics in Medicine Cardiovascular Diseases [electronic Resource], 2006, 10, E10.	0.1	1
693	Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. European Heart Journal, 2005, 26, 723-727.	2.2	140
694	Identification of Male Cardiomyocytes of Extracardiac Origin in the Hearts of Women with Male Progeny: Male Fetal Cell Microchimerism of the Heart. Journal of Heart and Lung Transplantation, 2005, 24, 2179-2183.	0.6	78
695	NT-ProBNP Reduction Percentage During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality. Journal of Cardiac Failure, 2005, 11, S3-S8.	1.7	80
696	The Efficacy of Colchicine in the Treatment of Recurrent Pericarditis Related to Postcardiac Injury (Postpericardiotomy and Postinfarcted) Syndrome: A Multicenter Analysis. Cardiology, 2004, 4, 141-144.	0.3	3
697	Cardiac chimerism in recipients of peripheral-blood and bone marrow stem cells. European Journal of Heart Failure, 2004, 6, 399-402.	7.1	22
698	Atrial Fibrillation Is Associated With Increased Spontaneous Calcium Release From the Sarcoplasmic Reticulum in Human Atrial Myocytes. Circulation, 2004, 110, 1358-1363.	1.6	301
699	N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. European Journal of Heart Failure, 2004, 6, 301-308.	7.1	169
700	N-terminal pro-brain natriuretic peptide reflects pulmonary capillary leakage in patients with acute dyspnea. American Journal of Cardiology, 2004, 94, 669-670.	1.6	17
701	Value of electrocardiographic algorithm based on “ups and downs” of ST in assessment of a culprit artery in evolving inferior wall acute myocardial infarction. American Journal of Cardiology, 2004, 94, 709-714.	1.6	87
702	New Insights into Elastin and Vascular Disease. Trends in Cardiovascular Medicine, 2003, 13, 176-181.	4.9	145

#	ARTICLE	IF	CITATIONS
703	Detecting Vulnerable Plaque Using Peripheral Blood: Inflammatory and Cellular Markers. <i>Journal of Interventional Cardiology</i> , 2003, 16, 231-242.	1.2	33
704	Effects of insulin-like growth factor-I on cultured human coronary artery smooth muscle cells. <i>Growth Hormone and IGF Research</i> , 2003, 13, 246-253.	1.1	14
705	Distinct left bundle branch block pattern in ischemic and non-ischemic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2003, 5, 165-170.	7.1	19
706	A critical role for elastin signaling in vascular morphogenesis and disease. <i>Development (Cambridge)</i> , 2003, 130, 411-423.	2.5	400
707	Coronary smooth muscle reactivity to muscarinic stimulation after ischemia-reperfusion in porcine myocardial infarction. <i>Journal of Applied Physiology</i> , 2003, 95, 81-88.	2.5	7
708	Host cell-derived cardiomyocytes in sex-mismatch cardiac allografts. <i>Cardiovascular Research</i> , 2002, 56, 404-410.	3.8	51
709	The clinical significance of markers of coagulation in acute coronary syndromes. , 2002, , 355-364.		0
710	Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. <i>Atherosclerosis</i> , 2002, 163, 89-98.	0.8	76
711	Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia. <i>Journal of the American College of Cardiology</i> , 2001, 38, 562-568.	2.8	18
712	Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2001, 345, 1022-1029.	27.0	509
713	New approaches to the pharmacological treatment of angina. <i>Current Opinion in Pharmacology</i> , 2001, 1, 151-158.	3.5	2
714	Insulin-Like Growth Factor Binding Protein-4 Protease Produced by Smooth Muscle Cells Increases in the Coronary Artery After Angioplasty. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 335-341.	2.4	136
715	Gene therapy for myocardial angiogenesis: Has it come of age?. <i>Current Atherosclerosis Reports</i> , 2000, 2, 373-379.	4.8	3
716	The Insulin-Like Growth Factor Axis. <i>Circulation Research</i> , 2000, 86, 125-130.	4.5	392
717	D -Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. <i>American Heart Journal</i> , 2000, 140, 379-384.	2.7	105
718	Elevated Levels of Plasmin- α 2 Antiplasmin Complexes in Unstable Angina. <i>Thrombosis and Haemostasis</i> , 1999, 81, 865-868.	3.4	15
719	Colchicine for large pericardial effusion. <i>Clinical Cardiology</i> , 1998, 21, 143-144.	1.8	28
720	Electrocardiographic and Clinical Precursors of Ventricular Fibrillation: Chain of Events. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 410-417.	1.7	17

#	ARTICLE	IF	CITATIONS
721	Idiopathic Dilated Cardiomyopathy: Molecular Basis and Distilling Complexity to Advance. , 0, , .	0	
722	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ, The, 0, , e068424.	6.0	18
723	Biomarkers in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 8, .	3.0	16
724	Atrial Mitral and Tricuspid Regurgitation: Sex Matters. A Call for Action to Unravel the Differences Between Women and Men. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6
725	The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0